Barclays’s Phio Pharmaceuticals PHIO Stock Holding History

Barclays’s Portfolio PHIO Stock Details PHIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$237	Buy	+231	New	+$263	﹤0.01%	5090
2025 Q2	–	Sell	-5	Closed	-$7	–	5466
2025 Q1	$7	Sell	5 -198	-98%	-$366	﹤0.01%	5186
2024 Q4	$365	Buy	+203	New	+$552	﹤0.01%	5166
2014 Q3	–	Hold	0	–	-$8K	–	7782
2014 Q2	–	Hold	0	–	–	–	6940
2014 Q1	–	Hold	0	–	–	–	7280

Other funds holding PHIO

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Barclays's PHIO Position: Q2 2026 in Review

Barclays opened a new position in Phio Pharmaceuticals (PHIO) in Q2 2026: 231 shares worth $237. The stake represents ﹤0.01% of the portfolio and ranks #5090 among its holdings. This is a return to the name: Barclays previously reported a position in PHIO as recently as Q1 2025.

Barclays first reported a position in PHIO in Q4 2024 and has held it in 3 quarters since. The position peaked at $365 in Q4 2024. 24 funds tracked by Wall St. Rank hold PHIO as of Q2 2026.

Barclays held 231 shares of Phio Pharmaceuticals worth $237 as of Q2 2026.
Phio Pharmaceuticals was a new Barclays position in Q2 2026.
Phio Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5090 holding.
Barclays first reported a position in Phio Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
Barclays's Phio Pharmaceuticals position peaked at $365 in Q4 2024.
24 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.